Skip to contentUniversity of Michigan Health System - link
Department of Internal Medicine - link
INFECTIOUS DISEASES S
search this site
 

About Us



Info for Patients




Referring Physicians




Our Faculty




Education & Research




HIV/AIDS Treatment Program

What's Inside/Appt Scheduling
What's New
In the Spotlight
Take a Look
Links
Web Resources



More News




Internal Resources




Internal Medicine Divisions

 
Clinical Trials

Clinical Trials

Be sure to visit the University of Michigan’s main gateway to clinical research trials:

Engage http://www.umengage.org/

There you can find trials actively recruiting at U of M and general information about research and how to participate.

For specific information on HIV research you can also speak with your medical provider at your next appointment or research personnel at 734-647-9830

Current Research Seeking HIV+ Individuals

Molecular Mechanisms of HIV Disease Pathogenesis I

Sponsor: National Institutes of Health

Goal: On therapy viral load decreases, but once stopped viral load becomes high again. Where is the virus waiting in the body when is it “undetectable” in the blood? This study suggests it may be bone marrow.

Method: A sample of bone marrow is taken from the hip. Requires a 1 hour visit in the hospital for the procedure.

Recruiting: 10 people with viral load over 50,000 c/mL and no serious illness.


IMPACT: I50L mutation on a failed Reyataz (atazanavir) regimen

Sponsor: Bristol-Myers Squibb

Goal: Therapy can become ineffective due to the development of resistance when the virus mutates to get around the drug. Tests like a genotype can detect these mutations and provide your doctor information for a better regimen for you. This study suggests one specific mutation called the I50L substitution occurs with Reyataz, and seeks to better understand treatment options.

Method: A blood sample is taken to test. Requires 1 blood draw in Taubman Center.

Recruiting: People taking Reyataz with a viral load over 1,000 c/mL.

POEM

Sponsor: Pfizer

Goal: Long term data collection on the FDA approved Maraviroc. To track the rates of •CDC Category C Opportunistic Infections •Viral encephalitis •All malignancies •Liver failure •Myocardial infarction or ischemia •Rhabdomyolysis •Death from any cause.

Method: There are no special appointments. Patients come to their normal clinical appointments in Taubman Center and the data is collected from the medical record.

Recruiting: Any patient in need of salvage therapy considering Maraviroc.




 
 
 
   
 
   

U-M Medical School
| Hospitals & Health Centers | U-M | TEXT-ONLY

University of Michigan Health System
1500 E. Medical Center Drive  Ann Arbor, MI 48109   734-936-4000
(c) copyright Regents of the University of Michigan
Template developed & maintained by: Public Relations & Marketing Communications
Contact UMHS

 
The University of Michigan Health System web site does not provide specific medical advice and does not endorse any medical or professional service obtained through information provided on this site or any links to this site.
Complete disclaimer and Privacy Statement

UMHS HOME

Health Topics A-Z

For Patients & Families

For Health Professionals

Search Tools & Index